Message #21 From:
NewsBot Date: January 3, 2007 05:00:00 AM
PANC News Panacos to Present at 2007 JPMorgan Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company
dedicated to developing the next generation of antiviral therapeutic
products, will present at the 2007 JPMorgan Healthcare Conference to be
held January 8-11 at the Westin St. Francis Hotel in San Francisco, CA.
Peyton Marshall, Acting CEO and Chief Financial Officer will present a
corporate overview on Wednesday, January 10 at 9:30 a.m. PST.
A link to the webcast of Panacos' presentation will be available for 30
days on the Company's web site at www.panacos.com.
About Panacos
Panacos is developing the next generation of anti-infective products
through discovery and development of small molecule oral drugs for the
treatment of HIV and other major human viral diseases. HIV infects
approximately 1.7 million people in North America and Western Europe and
approximately 40 million people worldwide. Approximately 650,000
patients are treated annually for HIV in the United States and Western
Europe. Resistance to currently available drugs is one of the most
pressing problems in HIV therapy and the leading cause of treatment
failure. Panacos' proprietary discovery technologies are designed to
combat resistance by focusing on novel targets in the virus life cycle,
including virus maturation and virus fusion.
Panacos' lead candidate, bevirimat (PA-457), is the first in a new class
of oral HIV therapeutics under development called maturation inhibitors,
discovered by Panacos scientists and their academic collaborators. Based
on its novel mechanism of action, bevirimat is designed to have potent
activity against a broad range of HIV, including strains that are
resistant to existing classes of drugs. The Company has completed seven
clinical studies of bevirimat in over 300 subjects, showing significant
reductions in viral load in HIV-infected subjects and a promising safety
profile, and is currently in Phase 2b clinical trials.
